Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Karyopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical company that discovers and develops novel drugs for the treatment of cancer and other diseases. The company develops small molecule selective inhibitor of nuclear export compounds that inhibit the nuclear export protein XPO1. Its pipeline drug candidates include oral selinexor, oral verdinexor, oral KPT-8602 and oral KPT-9274. Karyopharm Therapeutics drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and gynecological malignancies. The company operates across the US and Germany. Karyopharm Therapeutics is headquartered in Newton, Massachusetts, the US.

Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karyopharm Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Karyopharm Therapeutics Raises US$67.2 Million In Series B Venture Financing 12
Partnerships 14
Veristat Enters into Agreement with Karyopharm Therapeutics 14
Licensing Agreements 15
Antengene Enters into Licensing Agreement with Karyopharm Therapeutics 15
ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 16
Equity Offering 17
Karyopharm Therapeutics Raises USD155.2 Million in Prices Public Offering of Shares 17
Karyopharm Therapeutics Files Registration Statement for Public Offering of Securities for up to USD250 Million 19
Karyopharm Therapeutics to Raise up to USD75 million in Public Offering of Shares 20
Karyopharm Therapeutics Raises USD40 million in Public Offering of Shares 21
Karyopharm Therapeutics to Raise up to USD50 Million in Public Offering of Shares 23
Karyopharm Therapeutics Raises USD97.4 Million in Public Offering of Shares 25
Karyopharm Therapeutics Raises USD120.88 Million in Public Offering of Shares 27
Karyopharm Therapeutics Completes Underwriters Exercise Of Full Over-Allotment Option Of IPO For US$125 Million 29
Asset Transactions 31
Biogen Acquires Rights to KPT-350 from Karyopharm Therapeutics 31
Karyopharm Therapeutics Inc - Key Competitors 32
Karyopharm Therapeutics Inc - Key Employees 33
Karyopharm Therapeutics Inc - Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
May 10, 2018: Karyopharm Reports First Quarter 2018 Financial Results and Highlights Recent Progress 35
Mar 15, 2018: Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress 38
Nov 02, 2017: Karyopharm Reports Third Quarter 2017 Financial Results and Highlights Recent Progress 41
Aug 08, 2017: Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress 44
May 04, 2017: Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress 45
Corporate Communications 48
Sep 12, 2017: Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 48
Apr 03, 2017: Karyopharm Announces Management Change 50
Product News 51
12/10/2017: Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting 51
12/10/2017: Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting 53
09/20/2017: Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma 56
Product Approvals 58
Apr 10, 2018: Karyopharms Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma 58
Clinical Trials 59
May 17, 2018: Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting 59
May 16, 2018: Karyopharm to Present Selinexor Phase 2 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting 61
Apr 30, 2018: Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma 63
Mar 19, 2018: Karyopharm to Present Preclinical Data On Eltanexor at the American Association for Cancer Research 2018 Annual Meeting 65
Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting 66
Mar 19, 2018: Karyopharm to Present Preclinical Data on Selinexor at the American Association for Cancer Research 2018 Annual Meeting 67
Jan 31, 2018: Multiple Myeloma Research Foundation (MMRF) and Karyopharm Collaboration Drives the Advancement of Selinexor, a First-In-Class, Next-Generation Myeloma Therapy 69
Dec 10, 2017: Karyopharm Presents Data On Selinexor (KPT-330) At The American Society of Hematology 2017 Annual Meeting 70
Nov 01, 2017: Karyopharm to Present Phase 1b/2 STOMP Clinical Data at the American Society of Hematology 2017 Annual Meeting 71
Sep 08, 2017: Karyopharm Announces Presentation of KPT-9274 Clinical Data at European Society of Medical Oncology 2017 Annual Meeting 74
Sep 08, 2017: Karyopharm Announces Presentation of Selinexor Clinical Data at European Society of Medical Oncology 2017 Annual Meeting 75
Aug 30, 2017: Karyopharm Announces the Presentation of KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting 76
Aug 30, 2017: Karyopharm Announces the Presentation of Selinexor Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting 77
Aug 08, 2017: Karyopharm Provides Update on Selinexor (KPT-330) 78
Jun 23, 2017: Karyopharm Reports Updated Phase 2b SADAL Data for Selinexor in Diffuse Large B-Cell Lymphoma at the 2017 European Hematology Association Annual Meeting 80
Jun 07, 2017: Karyopharm Doses First Patient in Pivotal Phase 3 BOSTON Study Evaluating Selinexor in Patients with Relapsed/Refractory Multiple Myeloma 82
May 18, 2017: Karyopharms Phase 2b SADAL Data Evaluating Selinexor in Diffuse Large B-Cell Lymphoma Selected for Oral Presentation at the 2017 European Hematology Association Annual Meeting 83
Apr 04, 2017: Karyopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting 84
Appendix 86
Methodology 86
About GlobalData 86
Contact Us 86
Disclaimer 86

List Of Tables

List of Tables
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karyopharm Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Karyopharm Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Karyopharm Therapeutics Raises US$67.2 Million In Series B Venture Financing 12
Veristat Enters into Agreement with Karyopharm Therapeutics 14
Antengene Enters into Licensing Agreement with Karyopharm Therapeutics 15
ONO Pharma Enters into Licensing Agreement with Karyopharm Therapeutics 16
Karyopharm Therapeutics Raises USD155.2 Million in Prices Public Offering of Shares 17
Karyopharm Therapeutics Files Registration Statement for Public Offering of Securities for up to USD250 Million 19
Karyopharm Therapeutics to Raise up to USD75 million in Public Offering of Shares 20
Karyopharm Therapeutics Raises USD40 million in Public Offering of Shares 21
Karyopharm Therapeutics to Raise up to USD50 Million in Public Offering of Shares 23
Karyopharm Therapeutics Raises USD97.4 Million in Public Offering of Shares 25
Karyopharm Therapeutics Raises USD120.88 Million in Public Offering of Shares 27
Karyopharm Therapeutics Completes Underwriters Exercise Of Full Over-Allotment Option Of IPO For US$125 Million 29
Biogen Acquires Rights to KPT-350 from Karyopharm Therapeutics 31
Karyopharm Therapeutics Inc, Key Competitors 32
Karyopharm Therapeutics Inc, Key Employees 33
Karyopharm Therapeutics Inc, Subsidiaries 34

List Of Figures

List of Figures
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Karyopharm Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Karyopharm Therapeutics Inc (KPTI) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Karyopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical company that discovers and develops novel drugs for the treatment of cancer and other diseases. The company develops small molecule selective

USD 250 View Report

Karyopharm Therapeutics Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Karyopharm Therapeutics Inc Company Profile is a detailed strategic and analytical report on Karyopharm Therapeutics Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Nuo Therapeutics Inc (AURX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nuo Therapeutics Inc (Nuo Therapeutics), formerly Cytomedix, is a biomedical company that specializes in biodynamic therapies in the area of wound care. It focuses on commercializing cell-based technologies, which bind

USD 250 View Report

Assertio Therapeutics Inc (DEPO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Assertio Therapeutics Inc (Assertio), formerly Depomed Inc, is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain and other diseases of the central nervous system.

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available